Urokinase plasminogen activator: a prognostic marker in multiple types of cancer.
about
Quantitative analysis of human kallikrein gene 14 expression in breast tumours indicates association with poor prognosisFisetin inhibits migration and invasion of human cervical cancer cells by down-regulating urokinase plasminogen activator expression through suppressing the p38 MAPK-dependent NF-κB signaling pathwayInterleukin enhancer-binding factor 3 promotes breast tumor progression by regulating sustained urokinase-type plasminogen activator expressionSoluble urokinase-type plasminogen activator receptor inhibits cancer cell growth and invasion by direct urokinase-independent effects on cell signaling.Dependence on endocytic receptor binding via a minimal binding motif underlies the differential prognostic profiles of SerpinE1 and SerpinB2 in cancer.Expression of proteinases and inhibitors in human breast cancer progression and survival.Clinical uses of tumor markers: a critical review.Urokinase-type plasminogen activator and its receptor synergize to promote pathogenic proteolysis.Regulation of arterial remodeling and angiogenesis by urokinase-type plasminogen activator.Urokinase plasminogen activator induces pro-fibrotic/m2 phenotype in murine cardiac macrophagesImmunohistochemical expression of uPA, uPAR, and PAI-1 in breast carcinoma. Fibroblastic expression has strong associations with tumor pathology.Protease-activated drug development.Microenvironmental and cellular consequences of altered blood flow in tumours.Development of a Mammalian suspension culture for expression of active recombinant human urokinase-type plasminogen activator.Pharmacological inhibition of DNA methylation induces proinvasive and prometastatic genes in vitro and in vivo.Enhanced cell migration and apoptosis resistance may underlie the association between high SERPINE1 expression and poor outcome in head and neck carcinoma patients.Plasminogen activator inhibitor-1 as a potential marker for the malignancy of colorectal cancer.The topology of plasminogen binding and activation on the surface of human breast cancer cellsIndependent prognostic value of angiogenesis and the level of plasminogen activator inhibitor type 1 in breast cancer patientsHigh tPA-expression in primary melanoma of the limb correlates with good prognosis.Protumor activities of the immune response: insights in the mechanisms of immunological shift, oncotraining, and oncopromotion.Expression of the inhibitory Ly49E receptor is not critically involved in the immune response against cutaneous, pulmonary or liver tumours.The CD-loop of PAI-2 (SERPINB2) is redundant in the targeting, inhibition and clearance of cell surface uPA activity.Overexpression of MMP-3 and uPA with Diminished PAI-1 Related to Metastasis in Ductal Breast Cancer Patients Attending a Public Hospital in Mexico CityForkhead transcription factor foxq1 promotes epithelial-mesenchymal transition and breast cancer metastasisUrokinase-type plasminogen activator and its receptor in colorectal cancer: independent prognostic factors of metastasis and cancer-specific survival and potential therapeutic targets.Radiation-inducible silencing of uPA and uPAR in vitro and in vivo in meningioma.Human papillomavirus type 16 E6 induces cervical cancer cell migration through the p53/microRNA-23b/urokinase-type plasminogen activator pathway.Association of tissue mRNA and serum antigen levels of members of the urokinase-type plasminogen activator system with clinical and prognostic parameters in prostate cancer.Gypenosides inhibits migration and invasion of human oral cancer SAS cells through the inhibition of matrix metalloproteinase-2 -9 and urokinase-plasminogen by ERK1/2 and NF-kappa B signaling pathways.Benzyl isothiocyanate (BITC) inhibits migration and invasion of human gastric cancer AGS cells via suppressing ERK signal pathways.Down-regulation of the expression of RB18A/MED1, a cofactor of transcription, triggers strong tumorigenic phenotype of human melanoma cells.CD95 ligand induces motility and invasiveness of apoptosis-resistant tumor cells.ESX induces transformation and functional epithelial to mesenchymal transition in MCF-12A mammary epithelial cells.Correlation between metastatic potential and variants from colorectal tumor cell line HT-29.Overexpression of urokinase-type plasminogen activator in human gastric cancer cell line (AGS) induces tumorigenicity in severe combined immunodeficient mice.Prostasin serine protease inhibits breast cancer invasiveness and is transcriptionally regulated by promoter DNA methylation.Association between the polymorphisms of urokinase plasminogen activation system and cancer risk: a meta-analysis.Cancer-stromal interactions in scirrhous gastric carcinoma.Deregulation of the miRNAs expression in cervical cancer: human papillomavirus implications.
P2860
Q24646799-0F6A7353-894F-4581-A4D8-97F0FF697AA3Q28386841-0907C5CD-528F-4318-BF9C-8BC9B5FD7C88Q28390678-ED5F8EFC-FCC9-465B-B9F4-DD5554503AE3Q30311208-E4537DDC-8807-4458-9BF9-5090058FDE35Q30502082-66ACF6C1-752B-46C9-A074-E5B60748429AQ33919059-AB679E9F-B612-49EF-BFD6-7400BC3A0AD1Q34307441-7876DDF4-45DF-43C0-A3DD-96200EA838EBQ34489359-AF35B37A-D24C-4FA4-B5E3-FAACF0DCDEB5Q34606581-BE4E3BAB-96AD-452E-8264-77A98D8A8F4CQ34639045-9DD20BB6-B9CD-4ED2-A43D-4684B87E1B2FQ35745789-3CA4EDF0-AA2C-426C-AE8A-3ACD5C7EDBFAQ35811508-C09477C5-3804-49F6-97C7-5947C333A855Q35904989-4EA0ED96-CDB4-4934-A204-985913FB8078Q36255134-985196CD-A092-4B08-874C-82215820C847Q36485293-AFC88590-64D7-4B91-A9E2-CA92EB7758E5Q36557197-FF161E7D-F2C4-4ADF-B0A7-9ECA8F2D6BB1Q36615378-CA03E432-4C24-4C3E-8CC5-C578C7EBD97FQ36643348-A4F497BC-5135-44AF-83D7-ECDEAE2D7771Q36647843-2F8C4AAA-476C-4404-A53B-A34D3941D2ECQ36692014-5A944991-01FF-4CEF-B6A7-1B4BCAD129BAQ36729107-E10061D2-232B-4549-87E1-89325A22A921Q37137278-701734DB-9DA1-4792-920A-CD33F2CCFDCCQ37219827-DC4C90E3-B0DB-47F0-924D-283C7E5E1FE7Q37448568-65F255F6-1DA2-4143-AA1D-F1039FFDCCA6Q37529876-14757190-3A5B-4A7D-B2A7-BCAD988DB269Q38308022-AAE46B1D-EA09-42A6-9CDC-C0889DF792DEQ39589853-29FF4A5F-47A3-4B48-B22E-CD82C80C331FQ39606694-FFC80F52-75AB-4925-8016-F124EF94AF5EQ39644934-830EE13E-3F05-48EC-8738-2EF7EEA4CA37Q39698775-BF06CEAF-DFE6-4697-ACF7-0CACE36A4D59Q39700912-7258DBBB-56FB-4140-8840-602F7401140FQ39879864-218E3234-C78E-4E88-A09E-4F6228228087Q39959143-D91DBE38-F522-4E38-9D21-5E2619892054Q40591635-E22B57EB-F1A6-422F-9350-8DA20AA43328Q40618623-0A5BF4B5-AF45-40DB-ABDE-403C14819A4CQ40749450-30A087DF-546A-4B66-B9BF-EFF5A8980807Q40759567-BCDFA5CF-AC79-492A-872B-E1FC809EAF1EQ40988377-F0714CB2-6C4D-4369-AFA2-80FE0916BBA8Q41581107-C143423C-CC73-44A3-A32F-D84E03509D5EQ41837402-A7B71956-261A-4D0E-8090-1F9767BD5924
P2860
Urokinase plasminogen activator: a prognostic marker in multiple types of cancer.
description
1999 nî lūn-bûn
@nan
1999 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
1999 թվականի հունիսին հրատարակված գիտական հոդված
@hy
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
name
Urokinase plasminogen activator: a prognostic marker in multiple types of cancer.
@ast
Urokinase plasminogen activator: a prognostic marker in multiple types of cancer.
@en
type
label
Urokinase plasminogen activator: a prognostic marker in multiple types of cancer.
@ast
Urokinase plasminogen activator: a prognostic marker in multiple types of cancer.
@en
prefLabel
Urokinase plasminogen activator: a prognostic marker in multiple types of cancer.
@ast
Urokinase plasminogen activator: a prognostic marker in multiple types of cancer.
@en
P2093
P2860
P1476
Urokinase plasminogen activator: a prognostic marker in multiple types of cancer.
@en
P2093
Maguire TM
McDermott EW
O'Higgins N
P2860
P304
P356
10.1002/(SICI)1096-9098(199906)71:2<130::AID-JSO14>3.0.CO;2-9
P577
1999-06-01T00:00:00Z